| Document |
Document Title |
|
WO/2024/037667A2 |
Disclosed are a fused ring heterocyclic compound represented by the following formula I, an optical isomer, a deuterated substance, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the subs...
|
|
WO/2024/040080A1 |
The present embodiments provide compounds of Formula I, compositions of the compounds, and methods for treating diseases such as cancer.
|
|
WO/2024/039860A1 |
The present disclosure provides 2,3,4,9-tetrahydro-lH-pyrido[3,4-b]indole derivatives of formula I as estrogen receptor modulators for the treatment of cancer.
|
|
WO/2024/039858A1 |
The present disclosure provides compounds that are estrogen receptor modulators (e.g., estrogen receptor agonists, estrogen receptor antagonists, and/or complete estrogen receptor antagonists), and uses thereof.
|
|
WO/2024/038398A1 |
The present invention provides a novel 5-fluoro-1-[(2-fluorophenyl) methyl]-1H-pyrazolo [3, 4-b] pyridine-3-carboximidamide formate compound of formula (IV) and process for preparation thereof. The present invention further provides for ...
|
|
WO/2024/040131A1 |
This disclosure provides compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a), (I-aa), (I-b), (I-bb), (I-c), (I-cc), (I-d), (I-dd), (I-e), (I-ee), (I-f), (I-g), or (I-h)), Formula (II) (e.g., (II-c), (II-cc), (II-d), (II-dd),...
|
|
WO/2024/040109A2 |
The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
|
|
WO/2024/034301A1 |
The present invention provides: a phenanthroline compound from which it is possible to obtain excellent electron injection ability and electron transportation ability when used in an electron injection layer of an organic electroluminesc...
|
|
WO/2024/032755A1 |
Provided are certain BCL-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2024/036101A1 |
Disclosed are compounds of Formula (I): or a salt thereof, wherein: X, Y, R1, R2, R4, R5, and R6 are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha...
|
|
WO/2024/032598A1 |
The present application relates to a TGF-β inhibitor compound and the use thereof. Specifically, disclosed in the present application is a compound as represented by formula (I), or an isotope-labeled compound thereof, or an optical iso...
|
|
WO/2024/034593A1 |
Provided is a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and/or lung cancer. The present inventors examined compounds useful as an active ingredient of a pharmaceutical compos...
|
|
WO/2024/034773A1 |
Provided are zwitterionic organic frameworks for a solid-state secondary battery, wherein the organic frameworks are composed of covalent bonds and have a zwitterionic structure.
|
|
WO/2024/036270A1 |
The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
|
|
WO/2024/032747A1 |
The present application relates to tricyclic compounds and medical use thereof. The structure is represented by formula (I). Specifically, the present application further relates to a preparation method for the compounds, a pharmaceutica...
|
|
WO/2024/032615A1 |
Disclosed are a crystal form of a pyridinopyrimidinone compound of formula I, a pharmaceutically acceptable salt thereof, and a crystal form of the pharmaceutically acceptable salt thereof, which have significant inhibitory effects on th...
|
|
WO/2024/036305A2 |
Provided herein is a synthetic process for preparing a compound of Formula I, or a salt thereof: (I) The disclosure further provides useful intermediates, pharmaceutically acceptable compositions, and salts of the compound of Formula I. ...
|
|
WO/2024/032661A1 |
The present invention relates to the technical field of medicine, in particular to a KIF18A inhibitor compound, a pharmaceutically acceptable salt thereof, an ester thereof or a stereoisomer thereof, a pharmaceutical composition and prep...
|
|
WO/2024/032529A1 |
Provided are a protein degradation agent and a preparation method therefor and a pharmaceutical use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a ...
|
|
WO/2024/032409A1 |
The present application relates to the use of a piperazine compound in combination with radiotherapy for the treatment of a tumor.
|
|
WO/2024/035627A1 |
The present disclosure provides heterocyclic amide and urea compounds and compositions thereof useful for inhibiting JAK2.
|
|
WO/2024/032689A1 |
The present disclosure relates to a compound of formula (I) or a salt thereof, an enantiomer thereof, a stereoisomer thereof, a solvate thereof, or a polymorph thereof, and use thereof. The present disclosure further relates to a pharmac...
|
|
WO/2024/033293A1 |
The present invention relates to acylhydrazides obtained in situ by enzymatic hydrolysis of the parent prodrug 2-(difluoromethyl)- or 2-(trifluoromethyl)-1,3,4- oxadiazole, in histone deacetylase 6 (HDAC6).
|
|
WO/2024/032569A1 |
The present invention provides a prodrug compound, a preparation method therefor and a use thereof. Specifically, the present invention provides a compound represented by formula (I), a preparation method therefor, and a use thereof as a...
|
|
WO/2024/032561A1 |
Described herein are inhibitors of cyclin-dependent kinase (CDK) 12 and/or CDK13 (and pharmaceutical compositions comprising the inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder ass...
|
|
WO/2024/032776A1 |
Provided are certain BCL-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2024/032782A1 |
Provided is a vaccine adjuvant containing a STING agonist and a use thereof. The vaccine adjuvant containing a STING agonist provided by the present invention can enhance an immune response, and is especially suitable for the prevention ...
|
|
WO/2024/033667A1 |
The present invention relates to visible light sensitive photoremovable protecting groups and their parent compounds X including a xanthene, xanthenium or related cores, represented by formula (Xa): (Xa) wherein the substituents are as d...
|
|
WO/2024/029489A1 |
Provided herein are compounds and compositions useful in inhibiting a receptor tyrosine kinase, KIT. The compounds and compositions provided herein are useful for the prevention or treatment of one or more KIT mediated diseases or cond...
|
|
WO/2024/027762A1 |
Disclosed in the present invention are a fused ring compound, and a preparation method therefor and a use thereof. The present invention provides the fused ring compound represented by formula (I), a stereoisomer thereof, or a pharmaceut...
|
|
WO/2024/030968A1 |
The present disclosure relates to protein degradation-inducing compounds for protooncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET useful in the treatment of diseases and disorder...
|
|
WO/2024/031089A1 |
The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
|
|
WO/2024/027795A1 |
An antibody-drug conjugate containing an Myc protein degradation agent bioactive compound, a preparation method therefor, and use thereof in preventing and/or treating diseases related to abnormal cell activity, including but not limited...
|
|
WO/2024/027703A1 |
Provided are a PRMT5 inhibitor, and a preparation method therefor and a use thereof. Specifically disclosed are a compound as shown in formula I, a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, and a use thereof in ...
|
|
WO/2024/027694A1 |
The present invention relates to a protein degradation agent, a preparation method therefor, and a use thereof. The protein degradation agent can degrade various proteins including c-Myc protein, and therefore can be used for prevention ...
|
|
WO/2024/026536A1 |
The present disclosure relates to a compound of formula (I), or an N-oxide, pharmaceutically acceptable salt, prodrug or stereoisomer thereof. The present disclosure also relates to pharmaceutical compositions comprising the compound. Th...
|
|
WO/2024/028727A1 |
The present invention discloses a novel type of highly potent ENPP-1 inhibitors for the treatment of various diseases particularly, cancer. These inventive inhibitors are small molecules. One of the novel structural features is incorpora...
|
|
WO/2024/028795A1 |
The present invention discloses novel compounds as defined by the general formula (I) that are useful for the treatment of diabetes mellitus, obesity, body weight reduction, insulin resistance etc. involving the agonism of the glucagon l...
|
|
WO/2024/030908A1 |
The present disclosure provides a method of treating an inflammatory disease/disorder, acute myeloid leukemia (AML), or myelodysplastic syndrome (MDS) in a subject comprising administering to the subject a compound that inhibits IRAKI an...
|
|
WO/2024/028519A1 |
The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, X, Y and A are as defined herein. These compounds are photodynamic agents that generates reactive oxygen species when subjected to UV radiation. The invention also...
|
|
WO/2024/027565A1 |
The present invention relates to a crystal form of a compound of formula (I), i.e. (2-((5-chloro-2-((2-methoxy-4-(9-methyl-3,9-diaza-spiro[5.5]
undecane-3-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimet
hylphosphine oxide. The present ...
|
|
WO/2024/028169A1 |
The present invention relates to novel thiophenolic compounds (I) which are useful in the treatment of proliferative and/or hyper-proliferative diseases. Preferably, the compounds of the present invention are endowed with inhibitory acti...
|
|
WO/2024/028744A1 |
The present invention describes a combination of a suitable prolyl hydroxylase inhibitors with a suitable thrombopoietin (TPO) receptor agonist for the treatment of Aplastic anemia (AA). The invention also describes the preparation of su...
|
|
WO/2024/027800A1 |
The present invention relates to a new compound as a 5-HT2A receptor inverse agonist, a preparation method therefor and a pharmaceutical composition. The present invention further relates to the use of the compound or the pharmaceutical ...
|
|
WO/2024/027116A1 |
Provided are compounds of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4, Q, n, and A are described herein, which are useful as Lp-PLA2 inhibitors, pharmaceutical compositions comprising the ...
|
|
WO/2024/026688A1 |
The present invention relates to an orange-red thermally activated delayed fluorescent material and a preparation method therefor. The material name is 4,4',4''-(dibenzo[f,h]pyrido[2,3-b]quinoxaline-3,6,11-triyl)
tri(N,N-diphenylaniline)...
|
|
WO/2024/028316A1 |
The present invention relates to 1H-pyrrolo[3,2-b]pyridine derivatives of formula (I) as irreversible inhibitors of mutant EGFR for the treatment of cancer. An exemplary compound is e.g. N-[2-({4-[3-(4-fluorophenyl)-1H-pyrrolo[3,2-b]pyri...
|
|
WO/2024/026540A1 |
Disclosed are compounds of Formula I and their use as inhibitors of the viral protease non-structural protein 5 (NSP5). Typically, the NSP5 is derived from a coronavirus, more typically from SARS-CoV-2. More particularly, the invention r...
|
|
WO/2024/028245A1 |
The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl -peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransfera...
|
|
WO/2024/026058A1 |
The present invention provides crystalline forms of (6S,7S)-6-fluoro-7-(2-fluoro-5-methylphenyl)-3-(tetrahydro-2
H-pyran-4-yl)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4(
1H,3H)-dione ("Compound I"). Also provided are related pharmace...
|
